BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9552050)

  • 1. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team.
    Dezube BJ; Von Roenn JH; Holden-Wiltse J; Cheung TW; Remick SC; Cooley TP; Moore J; Sommadossi JP; Shriver SL; Suckow CW; Gill PS
    J Clin Oncol; 1998 Apr; 16(4):1444-9. PubMed ID: 9552050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor.
    Figg WD; Pluda JM; Lush RM; Saville MW; Wyvill K; Reed E; Yarchoan R
    Pharmacotherapy; 1997; 17(1):91-7. PubMed ID: 9017768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma.
    Moore JD; Dezube BJ; Gill P; Zhou XJ; Acosta EP; Sommadossi JP
    Cancer Chemother Pharmacol; 2000; 46(3):173-9. PubMed ID: 11021733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma.
    Tulpule A; Scadden DT; Espina BM; Cabriales S; Howard W; Shea K; Gill PS
    J Clin Oncol; 2000 Feb; 18(4):716-23. PubMed ID: 10673512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma.
    Tulpule A; Yung RC; Wernz J; Espina BM; Myers A; Scadden DT; Cabriales S; Ilaw M; Boswell W; Gill PS
    J Clin Oncol; 1998 Oct; 16(10):3369-74. PubMed ID: 9779714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma.
    Gill PS; Tulpule A; Espina BM; Cabriales S; Bresnahan J; Ilaw M; Louie S; Gustafson NF; Brown MA; Orcutt C; Winograd B; Scadden DT
    J Clin Oncol; 1999 Jun; 17(6):1876-83. PubMed ID: 10561228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.
    Bhargava P; Marshall JL; Rizvi N; Dahut W; Yoe J; Figuera M; Phipps K; Ong VS; Kato A; Hawkins MJ
    Clin Cancer Res; 1999 Aug; 5(8):1989-95. PubMed ID: 10473076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
    Koon HB; Bubley GJ; Pantanowitz L; Masiello D; Smith B; Crosby K; Proper J; Weeden W; Miller TE; Chatis P; Egorin MJ; Tahan SR; Dezube BJ
    J Clin Oncol; 2005 Feb; 23(5):982-9. PubMed ID: 15572730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study.
    Cianfrocca M; Cooley TP; Lee JY; Rudek MA; Scadden DT; Ratner L; Pluda JM; Figg WD; Krown SE; Dezube BJ
    J Clin Oncol; 2002 Jan; 20(1):153-9. PubMed ID: 11773164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated liposomal doxorubicin as first line treatment in aids-related Kaposi's sarcoma: a real-life study.
    Dalu D; Fasola C; Ammoni L; De Francesco D; Cona MS; Rota S; Ferrario S; Gambaro A; Tosca N; Piva S; La Verde N
    J Chemother; 2021 Sep; 33(5):342-347. PubMed ID: 34060438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. All-trans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: results of a pilot phase II study.
    Gill PS; Espina BM; Moudgil T; Kidane S; Esplin JA; Tulpule A; Levine AM
    Leukemia; 1994; 8 Suppl 3():S26-32. PubMed ID: 7808021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study.
    Evans SR; Krown SE; Testa MA; Cooley TP; Von Roenn JH
    J Clin Oncol; 2002 Aug; 20(15):3236-41. PubMed ID: 12149296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy.
    Schwartsmann G; Sprinz E; Kromfield M; Kalakun L; Sander E; Prolla G; Di Leone L; Gerhardt L; Mans DR
    J Clin Oncol; 1997 May; 15(5):2118-24. PubMed ID: 9164226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma.
    Tulpule A; Groopman J; Saville MW; Harrington W; Friedman-Kien A; Espina BM; Garces C; Mantelle L; Mettinger K; Scadden DT; Gill PS
    Cancer; 2002 Jul; 95(1):147-54. PubMed ID: 12115328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly oral etoposide in patients with Kaposi's sarcoma associated with human immunodeficiency virus infection: a phase I multicenter trial of the AIDS Clinical Trials Group.
    Paredes J; Kahn JO; Tong WP; Feldstein ML; Lin S; Bennett JM; Metroka CE; Ratner L; Krown SE
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jun; 9(2):138-44. PubMed ID: 7749790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma.
    Fumagalli L; Zucchetti M; Parisi I; ViganĂ² MG; Zecca B; Careddu A; D'Incalci M; Lazzarin A
    Cancer Chemother Pharmacol; 2000; 45(6):495-501. PubMed ID: 10854138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.
    Herbst RS; Madden TL; Tran HT; Blumenschein GR; Meyers CA; Seabrooke LF; Khuri FR; Puduvalli VK; Allgood V; Fritsche HA; Hinton L; Newman RA; Crane EA; Fossella FV; Dordal M; Goodin T; Hong WK
    J Clin Oncol; 2002 Nov; 20(22):4440-7. PubMed ID: 12431966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index.
    Sprinz E; Caldas AP; Mans DR; Cancela A; DiLeone L; Dalla Costa T; Schwartsmann G
    Am J Clin Oncol; 2001 Apr; 24(2):177-84. PubMed ID: 11319295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study.
    Dezube BJ; Krown SE; Lee JY; Bauer KS; Aboulafia DM
    J Clin Oncol; 2006 Mar; 24(9):1389-94. PubMed ID: 16549833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers.
    Kreuter A; Rasokat H; Klouche M; Esser S; Bader A; Gambichler T; Altmeyer P; Brockmeyer NH
    Cancer Invest; 2005; 23(8):653-9. PubMed ID: 16377582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.